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Background: Osteoporosis is a condition of bones that leads to an increased susceptibility to fracture and
consequent painful morbidity. It has become a major issue of life quality worldwide. However, until now, the
molecular mechanism of this disease is far from being clear.
Methods: In this study, we obtained the gene expression profile of osteoporosis and controls from Gene
Expression Omnibus and identified differentially expressed genes (DEGs) using classical t-test method. Then,
functional enrichment analyses were performed to identify the dysregulated Gene Ontology categories and
dysfunctional pathways in osteoporosis patients compared to controls. Besides, the connectivity map was used to
identify compounds that induced inverse gene changes to osteoporosis.
Results: A total of 5581 DEGs were identified. We found these DEGs were enriched in 9 pathways by pathway
enrichment analysis, including focal adhesion and MAPK signaling pathway. Besides, sanguinarine was identified as
a potential therapeutic drug candidate capable of targeting osteoporosis.
Conclusion: Although candidate agents identified by our approach may be premature for clinical trials, it is clearly
a direction that warrants additional consideration.
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Osteoporosis is a condition of bones that leads to an
increased susceptibility to fracture and consequent pain-
ful morbidity [1,2]. The prevalence of osteoporosis
increases with age due to an imbalance between bone re-
sorption and bone formation during the bone remodel-
ing cycle. Osteoporosis affects up to 30% of women and
12% of men at some point in life and it is a major quality
of life issue worldwide [3].
The well accepted pathophysiological mechanisms for
osteoporosis include early apoptosis of osteoblasts [4] and
osteocytes [5,6], prolongation of the life span of osteoclasts
[7] and the imbalance between osteoblastogenesis and
adipogenesis of bone marrow mesenchymal stem cells [8].
Many factors influence the risk of osteoporosis, including* Correspondence: yuguiyong123@hotmail.com
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reproduction in any medium, provided the orpredominantly peak bone density along with other factors
such as genetic factors, body weight, diet, physical activity,
medication use, and coexisting disease [3,9,10]. Besides,
lack of estrogen, deficiency of calcium and vitamin D are
also important common causes of osteoporosis [11-14].
Various molecular signals were identified to regulate the
activation of osteoclasts. Osteoprotegerin (OPG) binds ac-
tivator for nuclear factor κB ligand (RANKL), and hence
suppresses its ability to increase bone resorption [15]. The
role of Wnt signaling pathway is recognized but less well
understood. Local production of eicosanoids and
interleukins is thought to participate in the regulation of
bone turnover, and excess or reduced production of these
mediators may underlie the development of osteoporosis
[16]. However, until now, the molecular mechanism of this
disease is far from being clear.
In the present study, we aim to explore the molecular
mechanism of osteoporosis using a computational bio-
informatics analysis of gene expression, and to identifyThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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didate agents identified by our approach may provide
the ground work for a new therapy approach for osteo-




The gene expression profile of GSE 35956 [17] was
downloaded from a public functional genomics data re-
pository Gene Expression Omnibus (GEO; http://www.
ncbi.nlm.nih.gov/geo/), which is based on the Affymetrix
GPL570 platform data (Affymetrix Human Genome
U133 Plus 2.0 Array). Only 10 genechips were available
for further analysis, including 5 genechips from human
mesenchymal stem cells (MSCs) of osteoporosis patients
and 5 genechips from human MSCs of non-osteoporotic
controls. The Human MSCs of elderly patients suffering
from osteoporosis were isolated from femoral heads after
low-energy fracture of the femoral neck. Control cells
were obtained from bone marrow of femoral heads of
middle-aged, non-osteoporotic donors after total hip
arthroplasty.
Pathway data
KEGG (Kyoto Encyclopedia of Genes and Genomes) is a
collection of online databases dealing with genomes, en-
zymatic pathways, and biological chemicals [18]. The
PATHWAY database records networks of molecular
interactions in the cells, and variants of them specific to
particular organisms (http://www.genome.jp/kegg/).
Small molecules data
The connectivity map (CMap) can be used to find
connections among small molecules sharing a mechanism
of action, chemicals and physiological processes, and
diseases and drugs [19]. It is the first installment of a
reference collection of gene-expression profiles from
cultured human cells treated with bioactive small mole-
cules, together with pattern-matching software to mine
these data. The CMap dataset comprises genomic profiling
data from 6100 treatment-control pairs (instances) involv-
ing 1309 bioactive molecules (perturbagens). We
downloaded all the profile data for further analysis.
Differentially expressed genes (DEG) analysis
For GSE 35956, we used R package (v.2.13.0) to analyze
the gene expression. The CEL source files from all
conditions were processed into expression estimates and
performed background correction and quartile data
normalization using RMA (Robust Multi-array Average)
algorithm [20]. Probe sets were mapped to national cen-
ter for biotechnology information (NCBI) entrez genes
using DAVID [21]. If there are multiple probe sets thatcorrespond to the same gene, the expression values of
those probe sets are averaged. We used the classical t-
test to identify differentially expressed genes and defined
p-value < 0.05 to be statistically significant.Go ontology analysis
Gene Ontology (GO) analysis has become a commonly
used approach for functional studies of large-scale gen-
omic or transcriptomic data [22]. To better understand
the functional relevance of the identified DEGs, we
performed GO enrichment analysis using goProfiles [23]
and searched for over-representation in GO categories
in three categories, namely biological process, molecular
function and cellular component.Pathway enrichment analysis
DAVID (The Database for Annotation, Visualization and
Integrated Discovery) consists of an integrated biological
knowledgebase and analytic tools aimed at systematically
extracting biological meaning from large gene/protein
lists [21]. We used the DAVID to identify over-
represented KEGG categories in pathways based on the
hypergeometric distribution with the count larger than 2
and the FDR less than 0.01.Small molecule identification
We first divided the DEGs into two groups: up-regulated
group and down-regulated group. Then, we selected the
top 500 significant DEGs in each group and performed
gene set enrichment analysis compared to the gene pro-
file of a treatment-control pair (instance) in CMap data-
base. The output consisted of a group of chemical
perturbagens with an enrichment score ranging from +1
and −1. The score represented the correlation between
the query signature profile (osteoporosis) and the gene
profile of a treatment-control pair. A high positive
connectivity score indicated that the corresponding
perturbagen induced the expression of the query signa-
ture (osteoporosis), whereas a high negative enrichment
score indicated reversal of expression of the query signa-
ture (osteoporosis) by the perturbagen. A zero or “null”
enrichment score indicated that no effect upon expres-
sion of the query signature was recorded.Results
Analysis of DEGs in osteoporosis
Publicly available microarray dataset of human MSCs
from osteoporosis and control were obtained from GEO
database. We used the classical t-test method to calculate
the p-values of all genes and defined p-value < 0.05 to be
statistically significant. Expressions of 5581 genes were
identified differed across osteoporosis and control group.
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In order to facilitate the functional annotation and ana-
lysis of large lists of genes in our result, we identified
over-represented GO categories in three ontologies
(Figure 1, Figure 2 and Figure 3). In the ontology of cel-
lular component, GO categories of cell and cell part tied
for first place in the enrichment (4982 genes). Besides, a
total of 3487 genes were enriched in the GO category of
organelle. In the ontology of biological process, the most
significant GO category was cellular process, and a total
of 4311 genes enriched in this category. In the ontology
of molecular function, the GO category of binding
included 4055 genes which was the most significant cat-
egory in this ontology. The second significant GO cat-
egory is catalytic activity (1730 genes).Identification of dysfunctional pathways in osteoporosis
We performed pathway enrichment analysis using the
online biological classification tool DAVID. A total of 9
dysfunctional pathways with p-value less than 0.01
were enriched (Table 1). The most significant dysfunc-
tional pathway was focal adhesion with p-value =
5.04E-04. The other significant pathways included
MAPK signaling pathway (p-value = 0.001953), allo-
graft rejection (p-value = 0.003975) and DNA replica-
tion (p-value= 0.003975).Figure 1 GO Enrichment of DEGs in cellular component ontology. The
ontology and the abscissa indicates the number of DEGs in each category.Identification of candidate small molecules
In order to identify candidate small molecules capable to
reverse the gene changes of osteoporosis, we performed
computational bioinformatics analysis of the derived
gene signature using the Connectivity Map. The
perturbagens from the CMap were analyzed according
to their permutated results, p-values, and enrichment
scores. A search against 6100 treatment-control pairs
(instances) representing 1309 bioactive small molecules
identified large amount small molecules which exhibited
positive or negative correlation to the query signature.
The top 20 significant small molecules were listed in
Table 2. In Table 2, the small molecule of sanguinarine
(enrichment score = −0.968) was associated with highly
significant negative scores and the small molecule of
isoflupredone was associated with highly significant
positive score (enrichment score = 0.95).Discussion
Gene expression profiling in disease reveals the underlying
gene activity changes contributing to the disease and
enables targets for therapeutic intervention to be identi-
fied. In this study, we investigated gene expression profile
in human MSCs from patients of osteoporosis and
controls, and then identified biologically active small
molecules capable to reverse gene changes of osteopo-ordinate indicates the enriched GO categories in cellular component
Figure 2 GO Enrichment of DEGs in biological process ontology. The ordinate indicates the enriched GO categories in biological process
ontology and the abscissa indicates the number of DEGs in each category.
Figure 3 GO Enrichment of DEGs in molecular function ontology. The ordinate indicates the enriched GO categories in molecular function
ontology and the abscissa indicates the number of DEGs in each category.
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Table 1 The enriched KEGG pathways
KEGG-ID Description P-Value
hsa04510 Focal adhesion 5.04E-04
hsa04010 MAPK signaling pathway 0.001953
hsa05330 Allograft rejection 0.003975
hsa03030 DNA replication 0.003975
hsa05211 Renal cell carcinoma 0.004548
hsa04912 GnRH signaling pathway 0.005447
hsa04720 Long-term potentiation 0.005452
hsa04110 Cell cycle 0.007658
hsa04120 Ubiquitin mediated proteolysis 0.008467
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show that a total of 5581 genes were differentially
expressed between osteoporosis and controls. In addition,
we identified large amount of small molecules which can
provide new ideas for the therapeutic studies in
osteoporosis.
Up to 5581 genes were identified differentially ex-
pressed between osteoporosis and control in our ap-
proach. These DEGs may play critical roles in the
initiation of osteoporosis, and investigation of them may
shed new lights on understanding of the molecular
mechanism of osteoporosis. Pathway enrichment ana-
lysis of these DEGs indicated a total of 9 pathways wereTable 2 Small molecules capable to reverse osteoporosis




















podophyllotoxin 0.807 0.00257dysregulated in the development of osteoporosis, includ-
ing focal adhesion and MAPK signaling pathway.
Focal adhesions, which are specialized sites of attach-
ment between cells and the extracellular matrix, play a
role in cell motility, cell proliferation, signal transduction
and have been proposed to function as mechanosensors
[24-26]. Osteoporosis is a result of an imbalance of bone
formation and resorption. In osteoporosis, the regenera-
tive capacity of bone is compromised, which may involve
altered osteoblast activity. This could be attributed to an
inappropriate synthesis and assembly of an extracellular
matrix (ECM), altered cell adhesion to the ECM, or be
due to inappropriate downstream activation of adhesion-
mediated signaling cascades through proteins such as
focal adhesion kinase (FAK). Perinpanayagam et al.
suggested that early adhesion-mediated events, such as
cell adhesion, attachment, and FAK signaling may be
altered in osteoporotic osteoblast cells [27]. In our re-
sult, focal adhesion was the most significant dysfunc-
tional pathways in the initiation of osteoporosis.
MAPK signaling pathways transduces a large variety of
external signals, leading to a wide range of cellular
responses, including growth, differentiation, inflamma-
tion and apoptosis [28]. Several studies have suggested
that MAPK signaling pathways contribute greatly to
osteoblast differentiation and bone formation via TGF-β
and bone morphogenic protein (BMP) signaling path-
ways. Lee et al. demonstrated that MAPK pathways con-
verge at the Runx2 gene to control mesenchymal
precursor cell differentiation following TGF-β induction
[29]. Recent study revealed that TGF-β signaling
promotes osteoprogenitor proliferation, early differenti-
ation, and commitment to the osteoblastic lineage
through the selective MAPKs pathways [30]. In addition,
MAPK dependent phosphorylation, TGF-β/BMP signal-
ing, and Runx2 subnuclear targeting converge to induce
the osteogenic phenotype [31].
The identification of a group of small molecules with
potential therapeutic efficacy for osteoporosis is an im-
portant observation of our work. Data in Table 2 shows
that sanguinarine (enrichment score = −0.968) was
associated with highly significant negative score, sug-
gesting that this small molecule is capable of targeting
osteoporosis. Sanguinarine, a component of sanguinaria
extract, has been shown to display antitumor and anti-
inflammatory properties in animals [32,33] and to inhibit
neutrophil function [34]. Madan et al. demonstrate that
sanguinarine is a potent suppressor of NF-kB activation
that blocks the phosphorylation and degradation of IkBα
[35]. Recently, it was discovered that the RANK/
RANKL/OPG system is an important signal transduction
pathway that regulates osteoclast formation [36].
Targeting of this pathway is a novel therapeutic ap-
proach in the management of osteoporosis. Therefore,
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ture development of novel treatments of osteoporosis.
However, further evaluation for their potential use in the
treatment of osteoporosis is still needed.
Conclusion
In conclusion, we have identified a total of 9 dysfunc-
tional pathways in the development of osteoporosis.
Among them, focal adhesion and MAPK signaling path-
way were the most significant ones. Besides, we have
identified that sanguinarine may be a therapeutic drug
candidate capable of targeting osteoporosis. Although it
may be premature to suggest that this drug might be
ready for clinical trials, it is clearly a direction that
warrants additional consideration.
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